Loading
Almost every clear-cell kidney cancer carries the CAIX protein. Image it with one radioactive antibody, then treat with the same antibody carrying a therapeutic isotope.
Nearly every clear-cell renal cell carcinoma expresses carbonic anhydrase IX as a direct consequence of VHL loss, so the antigen is near-universal and stable. This theranostic idea images it with 89Zr-girentuximab PET, validated for diagnosis in ZIRCON, and then treats with the same antibody carrying 177Lu for beta emission or 225Ac for targeted alpha therapy. The rationale combines a stable target, the PSMA precedent in prostate cancer, and radiation-induced immunogenic cell death in a cancer that already responds to immunotherapy. STARLITE-1 and STARLITE-2 are testing 177Lu-girentuximab with nivolumab or cabozantinib, and the proposed test is a randomised phase 2 of 177Lu-girentuximab plus nivolumab versus nivolumab alone; Telix Pharmaceuticals is the linked company.
Shares CAIX PET (89Zr-girentuximab), Telix Pharmaceuticals, Renal cell carcinoma.
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/